GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » Float Percentage Of Total Shares Outstanding

Celldex Therapeutics (STU:TCE2) Float Percentage Of Total Shares Outstanding : 86.37% (As of May. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Celldex Therapeutics's float shares is 56.93 Mil. Celldex Therapeutics's total shares outstanding is 65.91 Mil. Celldex Therapeutics's float percentage of total shares outstanding is 86.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Celldex Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Celldex Therapeutics's Institutional Ownership is 69.30%.

Celldex Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Celldex Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=56.93/65.91
=86.37%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics (STU:TCE2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ARVN NTLA SMMT ACAD JANX VCEL MLTX TGTX FTRE NVAX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
CLDX:USA
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Website
https://www.celldex.com
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics (STU:TCE2) Headlines

No Headlines